BriaCell Therapeutics Corp Company Review & Valuation

BCTXF
OTC Markets
Latest Price
3.53USD

About BriaCell Therapeutics Corp

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing approaches for the management of cancer.

Its lead product candidate is Bria-IMT that is in Phase I/IIA clinical trial for the patients with advanced breast cancer.

The trial was being conducted with the co-development of BriaDX, a companion diagnostic test.

The company is also conducting a combination study of Bria-IMT with pembrolizumab or ipilimumab for patients with advanced breast cancer.

In addition, it is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced stage breast cancer.

Further, the company has preclinical small molecule program that consists of various selective protein kinase C delta inhibitors for cancer and fibrotic diseases.

BriaCell Therapeutics Corp.

is headquartered in West Vancouver, Canada.

Industry
Biotechnology
HQ Location
West Vancouver, Canada

Stock Price

Price data not available for BriaCell Therapeutics Corp.

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl